Product Details
Source
Human IgG4 (S108P) Kappa Isotype Control (mAb) is a chimeric monoclonal antibody recombinantly expressed from HEK293, which combines the variable region of a mouse monoclonal antibody with Human constant domain.
Species
Human
Isotype
Human IgG4/kappa
Antibody Type
Recombinant Monoclonal
Specificity
This product is a specific antibody against DNP.
Application
ApplicationRecommended UsageELISA1-30 ng/mLPurity
95% as determined by SDS-PAGE.
95% as determined by SEC-MALS.
Purification
Protein A purified / Protein G purified
Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
25 mg or larger size will be supplied as liquid and shipped by dry ice. Please inquire the dry ice shipping cost.
Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
ACRO Quality Management System
Customers Also Viewed
Performance Data
SDS-PAGE

Human IgG4 (S108P) Kappa Isotype Control (mAb) on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95% (With Star Ribbon Pre-stained Protein Marker).
SEC-MALS

The purity of Human IgG4 (S108P) Kappa Isotype Control (mAb) (Cat. No. DNP-M3) is more than 95% and the molecular weight of this protein is around 135-155 kDa verified by SEC-MALS.
Report
Bioactivity-ELISA

Immobilized DNP-Albumin Conjugate at 10 μg/mL (100 μL/well) can bind Human IgG4 (S108P) Kappa Isotype Control (mAb) (Cat. No. DNP-M3) with a linear range of 1-15 ng/mL (QC tested).
Protocol
Customer Reviews Writing Reviews

Background
Recent Advances
[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521
















